Portal de Periódicos da CAPES

A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge

2021; Nature Portfolio; Volume: 6; Issue: 1 Linguagem: Inglês

10.1038/s41541-021-00392-7

2059-0105

Kathryn McGuckin Wuertz, Erica K. Barkei, Wei‐Hung Chen, Elizabeth J. Martinez, Inès Lakhal-Naouar, Linda L. Jagodzinski, Dominic Paquin‐Proulx, Gregory D. Gromowski, Isabella Swafford, Akshaya Ganesh, Ming Dong, Xiankun Zeng, Paul V. Thomas, Rajeshwer S. Sankhala, Agnes Hajduczki, Caroline E. Peterson, Caitlin Kuklis, Sandrine Soman, Lindsay Wieczorek, Michelle Zemil, Alexander Anderson, Janice M. Darden, Heather Hernandez, Hannah Grove, Vincent Dussupt, Holly R. Hack, Rafael De La Barrera, Stasya Zarling, James F. Wood, Jeffrey W. Froude, Matthew Gagné, Amy R. Henry, Elham Bayat Mokhtari, Prakriti Mudvari, Shelly J. Krebs, Andrew Pekosz, Jeffrey R. Currier, Swagata Kar, Maciel Porto, Adrienne Winn, Kamil Radzyminski, Mark G. Lewis, Sandhya Vasan, Mehul S. Suthar, Victoria R. Polonis, Gary R. Matyas, Eli Boritz, Daniel C. Douek, Robert A. Seder, Sharon P. Daye, Mangala Rao, Sheila A. Peel, Michael Joyce, Diane L. Bolton, Nelson L. Michael, Kayvon Modjarrad,

SARS-CoV-2 detection and testing

Abstract The emergence of SARS-CoV-2 variants of concern (VOC) requires adequate coverage of vaccine protection. We evaluated whether a SARS-CoV-2 spike ferritin nanoparticle vaccine (SpFN), adjuvanted with the Army Liposomal Formulation QS21 (ALFQ), conferred protection against the Alpha (B.1.1.7), and Beta (B.1.351) VOCs in Syrian golden hamsters. SpFN-ALFQ was administered as either single or double-vaccination (0 and 4 week) regimens, using a high (10 μg) or low (0.2 μg) dose. Animals were intranasally challenged at week 11. Binding antibody responses were comparable between high- and low-dose groups. Neutralizing antibody titers were equivalent against WA1, B.1.1.7, and B.1.351 variants following two high dose vaccinations. Dose-dependent SpFN-ALFQ vaccination protected against SARS-CoV-2-induced disease and viral replication following intranasal B.1.1.7 or B.1.351 challenge, as evidenced by reduced weight loss, lung pathology, and lung and nasal turbinate viral burden. These data support the development of SpFN-ALFQ as a broadly protective, next-generation SARS-CoV-2 vaccine.